Start-ups should think of the right fundraising strategy as early as possible – Now more than ever!

working strong with sharp axe

Fundraising doesn’t start with an e-mail to potential investors. Entrepreneurs should only connect with investors after intensive assessment of their project, including having their business case challenged and validated from a critical outside point-of-view. Founders are often focused on the development of their technology or assays and do not find the necessary time and resources for the fundraising strategy.

Our CEO Pascal Winnen, who is also an Innosuisse accredited Special Coach for Fundraising and Investor Relations, often reminds our start-ups of the Chinese proverb: “Sharpening the axe won’t delay the work”.

working strong with sharp axeConnecting with investors is like going for a job interview, it all starts with the entrepreneur herself! The first impression she leaves with the potential investor is key and probably influences the overall outcome. Scientifically driven founders need to think how to tell and sell their success story. The pitch deck is like a CV: it needs to be comprehensive and clear. Don’t be afraid to stand out of the crowd!

 

COVID-19 will most probably not have a positive impact for fundraising. This global coronavirus pandemic is new and a lot about it is still unknown. It’s hard to predict what the long-term economic impact of COVID-19 on the market will be. In the current situation, investors are expected to react more cautiously when it comes to early-stage and high-risk projects. We are already seeing that some investors are steering clear from the start-up financing space.

The bottom line: the situation in the stock markets is tense and uncertain. In these ambiguous times, start-ups need to plan for longer fundraising rounds and prepare accurately for their fundraising. Don’t hesitate to reach out to our start-up team if you need additional support.

 

Inquiries:

Hemex AG, Start-up scouting team

Franziska Stemmler

+41 61 927 28 02 / franziska.stemmler@hemex.ch

 

Sars-CoV-2 NOTICE:

As we are closely monitoring the ongoing COVID-19 pandemic, our main priority at HEMEX is the health and safety of our community and associates. Sharing the responsibility for the public´s health, we are taking every precaution possible to limit the spread of infection, while ensuring continuity of operations.

From this week forward, all HEMEX employees are encouraged to work from home. We fully support remote collaboration using a variety of  tele- and videoconference options. Our team can be contacted via the regular email or phone contact details during usual business hours.

Remaining 100% compliant with the latest information and guidelines from public health officials, we will continuously assess the situation and act accordingly.

In case of questions or uncertainties, please feel free to reach out to us at info@hemex.ch

Startups, apply for the W.A. de Vigier Award now!

W. A. de Vigier swiss startup award winners 2019

The W.A. de Vigier Award is the oldest and highest endowed prize for startups in Switzerland, giving away five awards of CHF 100’000 each. Applications are open until January 6th.

Since 1989, the foundation has distributed over CHF 11 million of seed money, resulting in more than 90 thriving Swiss startups, successful IPOs, multiple company exits and many newly created jobs. 

This year our portfolio company Sleepiz AG – with their revolutionary sleep disorder-screening device – was announced as one of the award winners.

For online registration follow the link below:

https://devigier.chW. A. de Vigier swiss startup award winners 2019

 

The ELANA Heart Bypass System Workshop

Elana Workshop Horizon 2020 AMT Medical and Hemex

The HEMEX team participated in a workshop organized by AMT Medical at the UMC Utrecht (Netherlands) in the first week of December. A team of world-renowned cardiac surgeons demonstrated the application of AMT’s ELANA (Excimer Laser Assisted Non-occlusive Anastomosis) Heart Bypass System on a beating porcine heart on LifeTec’s innovative cardiac simulator platform.

The ELANA Heart Bypass System is a uniquely designed surgical device, that connects a donor bypass vessel with a recipient coronary artery in a simplified procedure on a beating heart, without the need for arresting blood flow or complex hand suturing.

The SAFE-CAB clinical trial is designed to demonstrate safety and efficacy of minimally invasive CABG surgeries using the ELANA technique, in order to establish it as the new golden standard to obtain standardized, reproducible anastomosis and thus substantially improve patient outcomes and reduce health care costs.

Co-funded by the Horizon 2020 Framework Programme of the European Union and the Grant Agreement (GA) No. 869922.

 

 

HEMEX expands to China

Hemex CEO Pascal Winnen joined a visit to Henan China technology park

On 14th November 2019, our CEO Pascal Winnen signed a cooperation agreement with the Luoyang Science and Innovation Park in Henan, China’s most populated province.

Under the Agreement, HEMEX will support the property developer Forton Group with attracting innovative Swiss startups for its newly built 133’000 m2 life science park. In exchange, HEMEX and its clients will get access to Henan’s 108 million population to conduct clinical trials and receive governmental support to accelerate preclinical and clinical development projects, as well as granted access to significant non-dilutive research funding.

A big thank you to Dr. Robert Sum of the Standortförderung BL for leading this very efficient economic mission.

 

HEMEX awarded Horizon 2020 grant

career options in consulting life sciences startups

The European Commission has awarded a consortium led by AMT Medical including HEMEX with a 2.2 MEUR grant under its “Fast-Track to Innovation (FTI)” program.

Under the proposal HEMEX will plan, coordinate and execute a multicentric, pan-European study in order to obtain CE-mark for the Excimer Laser Assisted Non-occlusive Anastomosis (ELANA) Heart Bypass System in Patients undergoing Coronary Artery Bypass Grafts (CABG), with the goal of achieving market approval in less than 36 months.

For more information on the progress of this life-changing therapy, please contact franziska.stemmler@hemex.ch. If you need advice on obtaining non-dilutive funding, help with writing your proposal, or forming a consortium with experienced partners, get in touch with us.

Co-funded by the Horizon 2020 Framework Programme of the European Union and the Grant Agreement (GA) No. 869922.